Underlying the design of the Handbook of Psychopharmacology is a prejudice that the study of drug influences on the mind has advanced to a stage where basic research and clinical application truly mesh. These later volumes of the Handbook are structured according to this conception. In certain volumes, groups of drugs are treated as classes with chapters ranging from basic chemistry to clinical application. Other volumes are assembled around topic areas such as anxiety or affective disorders. Thus, besides chapters on individual drug classes, we have included essays addressing broad areas such…mehr
Underlying the design of the Handbook of Psychopharmacology is a prejudice that the study of drug influences on the mind has advanced to a stage where basic research and clinical application truly mesh. These later volumes of the Handbook are structured according to this conception. In certain volumes, groups of drugs are treated as classes with chapters ranging from basic chemistry to clinical application. Other volumes are assembled around topic areas such as anxiety or affective disorders. Thus, besides chapters on individual drug classes, we have included essays addressing broad areas such as "The Limbic-Hypothalamic-Pituitary-Adrenal System and Human Be havior" and "Peptides and the Central Nervous System. " Surveying these diverse contributions, one comes away with a sentiment that, far from being an "applied" science borrowing from fundamental brain chemistry and physiology, psychopharmacology has instead provided basic researchers with the tools and conceptual approaches which now are advancing neurobiology to a central role in modern biology. Especially gratifying is the sense that, while contributing to an understanding of how the brain functions, psychopharmacology is a discipline whose fruits offer genuine help to the mentally ill with promises of escalating benefits in the future. L. L. 1. S. D. 1. S. H. S. VB CONTENTS CHAPTER 1 Monoamine Oxidase Inhibitors: Animal Pharmacology RICHARD F. SQUIRES 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1. 1. Localization. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1. 2. Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1. 3. Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . 3 2. Inhibition of 5-HT and Catecholamine Synthesis. . . . . . . . 5 3. Inhibition of Spontaneous Firing of 5-HT Neurons. . . . . .Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
1 Monoamine Oxidase Inhibitors: Animal Pharmacology.- 1. Introduction.- 2. Inhibition of 5-HT and Catecholamine Synthesis.- 3. Inhibition of Spontaneous Firing of 5-HT Neurons.- 4. Inhibitory Effects on Paradoxical Sleep and Pontogeniculooccipital Waves.- 5. Effects on Growth and Development.- 6. Inhibition of Ovulation.- 7. Effects on Lordosis.- 8. Effects on Male Copulatory Behavior.- 9. 5-HT-Dependent Behavioral Syndromes.- 10. Potentiation of Indoleamine Hallucinogens.- 11. Tryptamine Potentiation.- 12. Potentiation of Phenethylamine Hallucinogens.- 13. Hypotensive Effects.- 14. Tyramine Potentiation.- 15. Interactions of the MAOIs with Reserpine and Tetrabenazine.- 16. Anticonvulsant Actions of MAOIs.- 17. References.- 2 Monoamine Oxidase, Monoamine-Oxidase-Inhibiting Drugs, and Human Behavior.- 1. Introduction.- 2. MAO-Inhibiting Drugs: Biologic, Physiologic, and Behavioral Effects in Man.- 3. Monoamine Oxidase in Human Brain and Other Tissues.- 4. Human Platelet Monoamine Oxidase.- 5. Possible Association between Platelet MAO Activity and General Personality and Behavioral Factors.- 6. References.- 3 Tricyclic and Monoamine Oxidase Inhibitor Antidepressants: Structure-Activity Relationships.- 1. Introduction.- 2. Tricyclic and Related Compounds.- 3. Monoamine Oxidase Inhibitors.- 4. MAOIs as Inhibitors of the Uptake of Biogenic Amines and Tricyclic Compounds as Inhibitors of Monoamine Oxidase.- 5. Summary and Perspective.- 6. References.- 4 Tricyclic Antidepressants: Animal Pharmacology (Biochemical and Metabolic Aspects).- 1. Introduction.- 2. Pharmacologic Test Procedures Predicting Clinical Antidepressant Activity.- 3. Mode of Interaction of Tricyclic Antidepressants with Adrenergic Mechanisms.- 4. Interaction of Tricyclic Antidepressants with Other Drugs.- 5.Effect of Tricyclic Antidepressants on Adaptive Regulation at Pre- and Postsynaptic Sites.- 6. Metabolic Fate of Tricyclic Antidepressants.- 7. Some General Considerations on iV-Demethylation of Tricyclic Antidepressants.- 8. Miscellaneous Pharmacologic Effects of Tricyclic Antidepressants.- 9. References.- 5 Tricyclic and Monoamine-Oxidase-Inhibitor Antidepressants: Clinical Use.- 1. Introduction.- 2. Tricyclic Antidepressants: Clinical Studies.- 3. Adverse Effects of Tricyclic Antidepressants.- 4. MAOI: Clinical Studies.- 5. Adverse Effects of the MAOIs.- 6. Treatment of the Acute Episode.- 7. Prophylaxis.- 8. Interactive Effects of Tricyclic Agents and Sociotherapy.- 9. Combined Drug Treatments.- 10. Other Uses of the Antidepressants.- 11. Current Practices and Future Needs.- 12. References.- 6 Lithium Pharmacology and Physiology.- 1. Introduction.- 2. Historical Review.- 3. Basic Chemistry and Biophysics.- 4. Mechanism of Action.- 5. Physiology.- 6. Interactions with Pharmaceuticals.- 7. Effects on Clinical Tests.- 8. Conclusion.- 9. References.- 7 Lithium: Clinical Considerations.- 1. Introduction.- 2. Lithium in Mania.- 3. Lithium in Acute Endogenous Depression.- 4. Use of Lithium in Psychiatric Disorders Other Than Mania or Depression.- 5. Use of Lithium in Disorders of Childhood and Adolescence.- 6. Preparations, Dosage, and Control.- 7. Toxicology of the Lithium Ion.- 8. References.- 8 Lithium Prophylaxis and Experimental Rubidium Therapy in Affective Disorders.- 1. Factors in Assessing Prophylaxis.- 2. Methodology of Prophylactic Trials.- 3. Early Trials.- 4. Double-Blind Trials.- 5. Prophylaxis in Depression.- 6. Considerations in Prophylaxis: Summary.- 7. The life Table.- 8. Rubidium in Psychiatry.- 9. Recent Studies.- 10. Endogenous Rubidium.- 11. ChronicAdministration.- 12. Rubidium-Lithium Interactions.- 13. A Membrane Transport Hypothesis.- 14. References.
1 Monoamine Oxidase Inhibitors: Animal Pharmacology.- 1. Introduction.- 2. Inhibition of 5-HT and Catecholamine Synthesis.- 3. Inhibition of Spontaneous Firing of 5-HT Neurons.- 4. Inhibitory Effects on Paradoxical Sleep and Pontogeniculooccipital Waves.- 5. Effects on Growth and Development.- 6. Inhibition of Ovulation.- 7. Effects on Lordosis.- 8. Effects on Male Copulatory Behavior.- 9. 5-HT-Dependent Behavioral Syndromes.- 10. Potentiation of Indoleamine Hallucinogens.- 11. Tryptamine Potentiation.- 12. Potentiation of Phenethylamine Hallucinogens.- 13. Hypotensive Effects.- 14. Tyramine Potentiation.- 15. Interactions of the MAOIs with Reserpine and Tetrabenazine.- 16. Anticonvulsant Actions of MAOIs.- 17. References.- 2 Monoamine Oxidase, Monoamine-Oxidase-Inhibiting Drugs, and Human Behavior.- 1. Introduction.- 2. MAO-Inhibiting Drugs: Biologic, Physiologic, and Behavioral Effects in Man.- 3. Monoamine Oxidase in Human Brain and Other Tissues.- 4. Human Platelet Monoamine Oxidase.- 5. Possible Association between Platelet MAO Activity and General Personality and Behavioral Factors.- 6. References.- 3 Tricyclic and Monoamine Oxidase Inhibitor Antidepressants: Structure-Activity Relationships.- 1. Introduction.- 2. Tricyclic and Related Compounds.- 3. Monoamine Oxidase Inhibitors.- 4. MAOIs as Inhibitors of the Uptake of Biogenic Amines and Tricyclic Compounds as Inhibitors of Monoamine Oxidase.- 5. Summary and Perspective.- 6. References.- 4 Tricyclic Antidepressants: Animal Pharmacology (Biochemical and Metabolic Aspects).- 1. Introduction.- 2. Pharmacologic Test Procedures Predicting Clinical Antidepressant Activity.- 3. Mode of Interaction of Tricyclic Antidepressants with Adrenergic Mechanisms.- 4. Interaction of Tricyclic Antidepressants with Other Drugs.- 5.Effect of Tricyclic Antidepressants on Adaptive Regulation at Pre- and Postsynaptic Sites.- 6. Metabolic Fate of Tricyclic Antidepressants.- 7. Some General Considerations on iV-Demethylation of Tricyclic Antidepressants.- 8. Miscellaneous Pharmacologic Effects of Tricyclic Antidepressants.- 9. References.- 5 Tricyclic and Monoamine-Oxidase-Inhibitor Antidepressants: Clinical Use.- 1. Introduction.- 2. Tricyclic Antidepressants: Clinical Studies.- 3. Adverse Effects of Tricyclic Antidepressants.- 4. MAOI: Clinical Studies.- 5. Adverse Effects of the MAOIs.- 6. Treatment of the Acute Episode.- 7. Prophylaxis.- 8. Interactive Effects of Tricyclic Agents and Sociotherapy.- 9. Combined Drug Treatments.- 10. Other Uses of the Antidepressants.- 11. Current Practices and Future Needs.- 12. References.- 6 Lithium Pharmacology and Physiology.- 1. Introduction.- 2. Historical Review.- 3. Basic Chemistry and Biophysics.- 4. Mechanism of Action.- 5. Physiology.- 6. Interactions with Pharmaceuticals.- 7. Effects on Clinical Tests.- 8. Conclusion.- 9. References.- 7 Lithium: Clinical Considerations.- 1. Introduction.- 2. Lithium in Mania.- 3. Lithium in Acute Endogenous Depression.- 4. Use of Lithium in Psychiatric Disorders Other Than Mania or Depression.- 5. Use of Lithium in Disorders of Childhood and Adolescence.- 6. Preparations, Dosage, and Control.- 7. Toxicology of the Lithium Ion.- 8. References.- 8 Lithium Prophylaxis and Experimental Rubidium Therapy in Affective Disorders.- 1. Factors in Assessing Prophylaxis.- 2. Methodology of Prophylactic Trials.- 3. Early Trials.- 4. Double-Blind Trials.- 5. Prophylaxis in Depression.- 6. Considerations in Prophylaxis: Summary.- 7. The life Table.- 8. Rubidium in Psychiatry.- 9. Recent Studies.- 10. Endogenous Rubidium.- 11. ChronicAdministration.- 12. Rubidium-Lithium Interactions.- 13. A Membrane Transport Hypothesis.- 14. References.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826